Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Carisma Therapeutics Inc. (CARM)
since 2015 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Carisma Therapeutics Inc..
Table 2 shows the detailed insider transactions.
This company's CIK number is 1485003.
Total stock buying since 2015: $0.
Total stock sales since 2015: $9,917,085.
Total stock option exercises since 2015: $923,390.
Table 3. Detailed insider trading at Carisma Therapeutics Inc. (CARM)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2025-10-07 | Klichinsky Michael (Chief Scientific Officer) | Sale | 56,982 | .25 | 14,473 |
| 2025-10-07 | Klichinsky Michael (Chief Scientific Officer) | Option Ex | 56,982 | .11 | 6,268 |
| 2025-10-03 | Klichinsky Michael (Chief Scientific Officer) | Sale | 119,347 | .26 | 31,030 |
| 2025-10-02 | Klichinsky Michael (Chief Scientific Officer) | Sale | 200,000 | .25 | 50,800 |
| 2025-10-01 | Klichinsky Michael (Chief Scientific Officer) | Sale | 165,000 | .26 | 42,405 |
| 2023-03-02 | Ryu Elly (Principal Accounting Officer) | Sale | 17,289 | .59 | 10,148 |
| 2023-03-02 | Macdonald Glen C (Chief Technology Officer) | Sale | 170,372 | .59 | 100,008 |
| 2023-03-02 | Macdonald Glen C (Chief Technology Officer) | Option Ex | 286,292 | .59 | 168,053 |
| 2023-03-02 | Forbes Monica (Chief Financial Officer) | Sale | 345,849 | .59 | 203,013 |
| 2023-03-02 | Forbes Monica (Chief Financial Officer) | Option Ex | 371,125 | .59 | 217,850 |
| 2023-03-02 | Cannell Thomas R (President and CEO) | Sale | 487,487 | .59 | 286,154 |
| 2023-03-02 | Cannell Thomas R (President and CEO) | Option Ex | 606,800 | .59 | 356,191 |
| 2023-03-02 | Sullivan Mark (General Counsel & Secretary) | Sale | 219,218 | .59 | 128,680 |
| 2023-03-02 | Sullivan Mark (General Counsel & Secretary) | Option Ex | 298,175 | .59 | 175,028 |
| 2023-02-21 | Ryu Elly (Principal Accounting Officer) | Sale | 7,159 | .59 | 4,202 |
| 2023-02-21 | Macdonald Glen C (Chief Technology Officer) | Sale | 25,927 | .59 | 15,219 |
| 2023-02-21 | Forbes Monica (Chief Financial Officer) | Sale | 61,862 | .59 | 36,312 |
| 2023-02-21 | Cannell Thomas R (President and CEO) | Sale | 53,727 | .59 | 31,537 |
| 2023-02-21 | Sullivan Mark (General Counsel & Secretary) | Sale | 39,831 | .59 | 23,380 |
| 2017-02-14 | Mccabe John J (Chief Financial Officer) | Sale | 1,399 | 2.10 | 2,937 |
| 2016-09-28 | Celniker Abbie | Sale | 10,031 | 3.00 | 30,093 |
| 2016-09-23 | Kania Edwin M Jr (10% Owner) | Sale | 67,071 | 3.13 | 209,932 |
| 2016-09-22 | Kania Edwin M Jr (10% Owner) | Sale | 376,351 | 3.17 | 1,194,914 |
| 2016-09-21 | Kania Edwin M Jr (10% Owner) | Sale | 322,723 | 3.75 | 1,210,211 |
| 2016-09-20 | Kania Edwin M Jr (10% Owner) | Sale | 53,917 | 3.39 | 182,778 |
| 2016-09-19 | Kania Edwin M Jr (10% Owner) | Sale | 9,700 | 3.31 | 32,107 |
| 2016-09-15 | Kania Edwin M Jr (10% Owner) | Sale | 2,681 | 4.16 | 11,152 |
| 2016-09-14 | Kania Edwin M Jr (10% Owner) | Sale | 44,011 | 4.18 | 183,965 |
| 2016-09-07 | Kania Edwin M Jr (10% Owner) | Sale | 93,727 | 4.51 | 422,708 |
| 2016-09-06 | Kania Edwin M Jr (10% Owner) | Sale | 35,770 | 4.63 | 165,615 |
| 2016-08-15 | Mccabe John J (Chief Financial Officer) | Sale | 1,170 | 4.80 | 5,616 |
| 2016-06-27 | Celniker Abbie (President and CEO) | Sale | 10,029 | 2.08 | 20,860 |
| 2016-06-27 | Tubridy Karen L (Chief Development Officer) | Sale | 4,372 | 2.08 | 9,093 |
| 2016-06-13 | Mva Investors, Llc (10% Owner) | Sale | 1,042,000 | 2.74 | 2,859,248 |
| 2016-02-16 | Mccabe John J (Senior Vice President, Finance) | Sale | 1,501 | .27 | 405 |
| 2015-12-28 | Celniker Abbie (President and CEO) | Sale | 10,155 | 2.85 | 28,941 |
| 2015-12-28 | Furfine Eric Steven (Chief Scientific Officer) | Sale | 4,652 | 2.85 | 13,258 |
| 2015-12-28 | Tubridy Karen L (Chief Development Officer) | Sale | 4,427 | 2.85 | 12,616 |
| 2015-05-08 | Jafco Super V3 Investment Limited Partnership (10% Owner) | Sale | 33,400 | 13.23 | 441,882 |
| 2015-02-02 | Jafco Super V3 Investment Limited Partnership (10% Owner) | Sale | 17,900 | 11.62 | 207,998 |
| 2015-01-30 | Jafco Super V3 Investment Limited Partnership (10% Owner) | Sale | 60,000 | 11.77 | 706,200 |
| 2015-01-29 | Jafco Super V3 Investment Limited Partnership (10% Owner) | Sale | 55,000 | 11.46 | 630,300 |
| 2015-01-28 | Jafco Super V3 Investment Limited Partnership (10% Owner) | Sale | 5,000 | 11.58 | 57,900 |
| 2015-01-27 | Jafco Super V3 Investment Limited Partnership (10% Owner) | Sale | 2,200 | 11.66 | 25,652 |
| 2015-01-26 | Jafco Super V3 Investment Limited Partnership (10% Owner) | Sale | 1,300 | 11.73 | 15,252 |
| 2015-01-23 | Jafco Super V3 Investment Limited Partnership (10% Owner) | Sale | 5,000 | 11.80 | 59,020 |
| 2015-01-22 | Jafco Super V3 Investment Limited Partnership | Sale | 5,000 | 11.84 | 59,210 |
| 2015-01-21 | Jafco Super V3 Investment Limited Partnership | Sale | 1,300 | 11.65 | 15,143 |
| 2015-01-16 | Jafco Super V3 Investment Limited Partnership | Sale | 4,400 | 12.01 | 52,861 |
| 2015-01-15 | Jafco Super V3 Investment Limited Partnership | Sale | 1,700 | 12.25 | 20,821 |
| 2015-01-13 | Jafco Super V3 Investment Limited Partnership | Sale | 4,100 | 12.45 | 51,036 |
Insider trading activities including stock purchases, stock sales, and option exercises
of CARM listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Carisma Therapeutics Inc. (symbol CARM,
CIK number 1485003) see
the Securities and Exchange Commission (SEC) website.